Literature DB >> 11427254

Nucleotide sequence analysis of varicella-zoster virus glycoprotein E epitope coding regions.

V Shankar1, S Fisher, B Forghani, A Vafai.   

Abstract

Varicella-zoster virus (VZV) glycoprotein E [gE] contains 623 amino acid residues. Fifty percent of the gE gene, codons 39 to 344 that encompasses two epitope coding regions e1 and c1, was sequenced and analyzed for variation among the 30 VZV isolates. A total of eleven isolates showed variance when compared with Dumas VZV strain sequence through base substitutions, with two isolates showing an amino acid change of tryptophan to arginine outside the coding regions of the epitopes e1 and c1 that are recognized by monoclonal antibodies 4F9 and c1, respectively. The results suggest that these epitopes were stable in the various VZV isolates. Thus, VZV glycoproteins with conserved epitopes are suitable candidates for both primary and booster vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427254     DOI: 10.1016/s0264-410x(01)00147-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Complete DNA sequence analyses of the first two varicella-zoster virus glycoprotein E (D150N) mutant viruses found in North America: evolution of genotypes with an accelerated cell spread phenotype.

Authors:  Charles Grose; Shaun Tyler; Geoff Peters; Joanne Hiebert; Gwen M Stephens; William T Ruyechan; Wallen Jackson; Johnathan Storlie; Graham A Tipples
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Novel varicella-zoster virus glycoprotein E gene mutations associated with genotypes A and D.

Authors:  Jonas Schmidt-Chanasit; Karoline Bleymehl; Susanne G Schäd; Gerd Gross; Rainer G Ulrich; Hans Wilhelm Doerr
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

3.  New variant of varicella-zoster virus.

Authors:  Graham A Tipples; Gwen M Stephens; Chris Sherlock; Margrit Bowler; Benny Hoy; Darrel Cook; Charles Grose
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.